Semaglutide, Tirzepatide, Retatrutide: The Three Generations of Weight-Loss Drugs, Compared

The question sounds simple: which weight-loss drug is best? But anyone who's spent more than twenty minutes looking into this has discovered that the answer depends entirely on what you mean by "best" – best efficacy, best tolerability, best access, best cost, best for someone with diabetes, best for someone without it.

We've gone through the clinical trial data across all three generations — semaglutide, tirzepatide, and retatrutide — to put the numbers in plain language. Not to tell you which to ask for, but to give you the map that makes that conversation with your prescriber actually useful.

One thing worth stating clearly before we get into it: these are prescription medications. Retatrutide isn't FDA-approved yet. None of them are available on Amazon. What is available are the supplements that help people get more out of whichever drug they're on — and we'll connect those dots at the end.

Generation One: Semaglutide (Ozempic, Wegovy, Rybelsus)

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone that does three things: suppresses appetite, slows gastric emptying so you feel full longer, and improves glucose regulation by prompting the pancreas to release insulin after meals.

It comes in multiple brand names that frequently confuse people. Ozempic is semaglutide approved for type 2 diabetes. Wegovy is the same molecule approved for weight management, at a slightly higher maximum dose (2.4 mg vs 2.0 mg). Rybelsus is the oral daily tablet version, approved for diabetes — it's less effective for weight loss than the injectable forms because oral absorption is lower.

Efficacy: In the STEP 1 trial — the landmark study that established semaglutide's weight-loss profile — participants without diabetes lost an average of 15.3 kg at 68 weeks. About 86% lost at least 5% of body weight, 50% lost at least 15%, and 32% lost at least 20%. A newer higher-dose formulation (Wegovy HD at 7.2 mg) has since shown 19% average loss at 72 weeks in a separate trial — narrowing the gap with tirzepatide at equivalent timeframes.

Diabetes population: In the STEP 2 trial — the same drug, same dose, in people with type 2 diabetes — average weight loss dropped to 9.6%. That's nearly 40% less than the non-diabetic population. This pattern repeats across the entire class and is worth flagging every time someone quotes a headline number without specifying which population it came from.

Beyond weight: Semaglutide has the most mature indication list of the three. The SELECT trial showed a 20% reduction in major adverse cardiovascular events in people with obesity and established heart disease but no diabetes — making semaglutide the first weight-loss drug to demonstrate hard cardiovascular benefit in a major outcomes trial. It's also approved for obesity-related fatty liver disease (MASH), and data from STEP-HFpEF showed improved physical function in people with obesity-related heart failure.

Cost: Brand-name Wegovy runs around $1,000/month without insurance. Compounded semaglutide from telehealth providers has ranged from $130–$300/month, though the FDA has cracked down on compounding as supply of the brand-name product normalized. See our compounded vs brand-name GLP-1 guide for the full breakdown.

Generation Two: Tirzepatide (Zepbound, Mounjaro)

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor — a second incretin hormone found in areas of the brain that regulate appetite. The dual mechanism appears to produce additive effects beyond what GLP-1 alone achieves.

Brand name structure mirrors semaglutide: Mounjaro is approved for type 2 diabetes, Zepbound is approved for weight management. Same active ingredient, different approval indications and insurance coverage implications.

Efficacy: In SURMOUNT-1 — the primary obesity trial with participants without diabetes — average weight loss at the highest dose (15 mg) was 20.9% at 72 weeks. 57% of participants lost at least 20% of their body weight. 36% lost at least 25%. The SURMOUNT-3 trial, which preceded treatment with 12 weeks of intensive lifestyle intervention, reported total average reduction of 26.6% combining both phases.

Head-to-head vs semaglutide: SURMOUNT-5 ran tirzepatide and semaglutide head-to-head in a randomized trial of adults with obesity but no diabetes. At 72 weeks, tirzepatide produced 20.2% average weight loss versus 13.7% with semaglutide — a 47% greater relative reduction. Waist circumference fell 18.4 cm versus 13.0 cm. This is the cleanest efficacy comparison available, and tirzepatide won on every primary and secondary endpoint.

Diabetes population: SURMOUNT-2 enrolled adults with obesity and type 2 diabetes. Average weight loss reached 15.7% — meaningful but again lower than the non-diabetic cohort, by roughly 5 percentage points.

Beyond weight: Tirzepatide's SURMOUNT-OSA trial showed 25–29 events-per-hour reductions in apnea-hypopnea index in people with moderate-to-severe sleep apnea, with up to 52% of patients showing resolution of the condition. Cardiovascular outcomes data is still pending.

Cost: Zepbound lists around $550–$650/month at retail. LillyDirect sells directly to cash-pay patients from $299–$449/month depending on dose. Compounded tirzepatide from telehealth providers has run $200–$400/month.

Generation Three: Retatrutide (Investigational — Not FDA-Approved)

Retatrutide adds a third hormone receptor to the mix: glucagon. The theory behind triple agonism is that glucagon receptor activation may increase energy expenditure at rest — essentially nudging the body to burn slightly more even while appetite suppression reduces calories in. If that mechanism holds at scale, it would explain why retatrutide's efficacy numbers sit above tirzepatide's.

It's developed by Eli Lilly and delivered as a once-weekly subcutaneous injection, same as semaglutide and tirzepatide.

Efficacy: Phase 2 data showed 24.2% mean weight loss at 48 weeks in adults with obesity but no diabetes. The TRIUMPH-4 phase 3 trial — in adults with obesity and knee osteoarthritis — showed 28.7% at 68 weeks, alongside a 74.3% reduction in WOMAC knee pain scores. A phase 3 diabetes trial (TRANSCEND-T2D-1) showed 16.8% weight reduction at 40 weeks.

What's still pending: Seven additional phase 3 readouts are expected across 2026 — including the primary obesity population trial (TRIUMPH-1), a cardiovascular outcomes study, and a direct head-to-head against tirzepatide. Regulatory submission is anticipated later in 2026.

Tolerability flag: The phase 3 data flagged dysesthesia — an altered skin sensation — in about 21% of participants on the highest dose. This side effect is relatively specific to retatrutide and not commonly seen with semaglutide or tirzepatide. Discontinuation due to adverse events was also higher at the highest dose (18.2% vs 4% with placebo).

Availability: Not available. Not legally prescribable. The FDA has issued warning letters about compounded retatrutide products. For a full breakdown, see our retatrutide explainer.

The One Pattern That Runs Through All Three

Every generation of this drug class produces lower weight loss in people with type 2 diabetes than in people without it. The gap is consistent: roughly 5–7 percentage points less on the same drug at comparable doses.

This matters because media coverage almost always leads with the higher (non-diabetic) number. If you have diabetes and your prescriber mentions semaglutide, the 15% headline figure from STEP 1 is the wrong benchmark — the 9.6% from STEP 2 is the relevant one. Same logic applies across the board.

The reason isn't fully understood, but metabolic dysregulation in type 2 diabetes appears to blunt some of the appetite-suppression and weight-loss response. It doesn't mean the drugs don't work for people with diabetes — they do, and the glucose control benefit is often substantial. It means the efficacy ceiling is lower.

The Lean Mass Problem Every Generation Shares

All three drugs produce lean mass loss alongside fat loss. The ratios are roughly similar: about 25% of total weight lost is lean tissue on tirzepatide (from SURMOUNT-1 body composition analyses), and about 36% on retatrutide in phase 2 data. Semaglutide's body composition data shows a similar pattern.

Faster and larger weight loss tends to worsen that ratio. If retatrutide ultimately delivers 28%+ average loss, it may carry a steeper lean mass cost than either predecessor — though that'll need confirmation in phase 3 body composition substudies.

The practical implication is the same regardless of which drug you're on: protein intake at 1.2–2.0g per kilogram of body weight daily, resistance training 2–3 times per week, and creatine supplementation all have direct clinical support for preserving lean mass during a caloric deficit.

For a full breakdown of what to take and when, our muscle loss prevention guide covers the evidence-based protocol.

What Happens When You Stop

Every generation also shares the same discontinuation profile: when the drug stops, a meaningful portion of the weight comes back. SURMOUNT-4 showed that people who stopped tirzepatide after achieving substantial loss regained weight back to roughly 10% below their original baseline. The STEP maintenance trial showed comparable regain with semaglutide.

This is one of the strongest arguments obesity medicine makes for treating these drugs as long-term therapy rather than a course you complete.

It's also why the supplement and lifestyle protocol matters from day one — those habits need to be in place before, not after, the drug is stopped. We looked at the discontinuation data in detail in stopping a GLP-1 medication.

Where Each Drug Fits Now

Semaglutide is the right starting point for most people. It's got the longest track record, the most approved indications, proven cardiovascular benefit, and the most data on long-term use. Cost and access are real barriers, but generic competition and policy shifts are changing the picture.

Tirzepatide is the step up for people who need more efficacy or who plateaued on semaglutide. The head-to-head data is clear. The tolerability profile is comparable. The cost is higher, but LillyDirect has made brand-name access more realistic than it was two years ago.

Retatrutide is the one to watch — but not yet available to watch on your scale. The approval window is 2026–2027 at the earliest. When it does arrive, it'll likely be positioned for people with higher obesity severity or specific complications where the additional efficacy justifies the higher tolerability risk profile.

The supplement stack that supports each of them is the same. Our best supplements for GLP-1 users guide covers the full protocol — protein, creatine, multivitamin, B12, magnesium, and more — with specific product picks available on Amazon.

‍